Identification of the mitochondrial protein ADCK2 as a therapeutic oncotarget of NSCLC

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The aarF domain containing kinase 2 (ADCK2) is a mitochondrial protein involved in fatty acid metabolism and coenzyme Q biosynthesis.
• Elevated ADCK2 expression in non-small cell lung cancer (NSCLC) correlates with reduced patient survival and poor response to immunotherapy.

Purpose of the Study:

• To investigate the role of ADCK2 in NSCLC progression and its potential as a therapeutic target.

Main Methods:

• Bioinformatic analysis of ADCK2 transcript levels in NSCLC.
• In vitro studies using ADCK2 knockdown (shRNA) and knockout (CRISPR/Cas9) in NSCLC cells.
• Assessment of cell viability, proliferation, cell cycle, migration, apoptosis, and mitochondrial function.
• In vivo studies using NSCLC xenograft models in nude mice.
• Analysis of Akt-mTOR signaling pathway.

Main Results:

• ADCK2 is overexpressed in NSCLC tissues and cells.
• ADCK2 depletion significantly inhibited NSCLC cell viability, proliferation, migration, and induced apoptosis.
• ADCK2 deficiency disrupted mitochondrial function, leading to cytochrome C release, depolarization, DNA damage, and reduced ATP.
• ADCK2 knockdown/knockout suppressed NSCLC xenograft growth in vivo.
• ADCK2 depletion inactivated the Akt-mTOR signaling pathway.

Conclusions:

• Overexpressed ADCK2 is crucial for NSCLC cell growth and survival.
• Targeting ADCK2 presents a promising therapeutic strategy for NSCLC.